BIO-key International Files 8-K on Financials
Ticker: BKYI · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1019034
| Field | Detail |
|---|---|
| Company | Bio Key International INC (BKYI) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
BIO-key International dropped an 8-K on August 14th detailing their financials. Check it out.
AI Summary
On August 14, 2024, BIO-key International, Inc. filed an 8-K report detailing its financial results and condition. The company, incorporated in Delaware, is involved in prepackaged software services and is headquartered in Wall, NJ.
Why It Matters
This filing provides investors with crucial updates on BIO-key International's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: medium — The filing is a standard 8-K for financial reporting, but the company's specific financial health and market position would determine the ultimate risk.
Key Players & Entities
- BIO-key International, Inc. (company) — Registrant
- August 14, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Wall, NJ (location) — Principal executive offices
- 732-359-1100 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is disclosed in this 8-K filing?
This 8-K filing primarily serves as a notification of the company's financial condition and results of operations, with the detailed financial statements and exhibits expected to be filed subsequently or referenced within the report.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on August 14, 2024.
What is BIO-key International, Inc.'s state of incorporation?
BIO-key International, Inc. is incorporated in Delaware.
Where are BIO-key International, Inc.'s principal executive offices located?
BIO-key International, Inc.'s principal executive offices are located at 3349 Highway 138, Building A, Suite E, Wall, NJ 07719.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (732) 359-1100.
Filing Stats: 517 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-08-14 21:03:31
Filing Documents
- bkyi20240814_8k.htm (8-K) — 26KB
- ex_715039.htm (EX-99.1) — 268KB
- logo.jpg (GRAPHIC) — 11KB
- 0001437749-24-026930.txt ( ) — 461KB
- bkyi-20240814.xsd (EX-101.SCH) — 3KB
- bkyi-20240814_def.xml (EX-101.DEF) — 12KB
- bkyi-20240814_lab.xml (EX-101.LAB) — 15KB
- bkyi-20240814_pre.xml (EX-101.PRE) — 12KB
- bkyi20240814_8k_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 14, 2024 BIO-key International, Inc. (the "Company") issued a press release announcing its financial results for its second quarter 2024. A copy of the press release issued by the Company on August 14, 2024 is attached as Exhibit 99. The information, including the exhibit attached hereto, in this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.
01. Financial Statements, Pro Forma Financial Information and Exhibit
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibit. (d) Exhibits. The following exhibit is furnished herewith: 99.1 Press Release, dated August 14, 2024, issued by the Company. 104 Cover Page Interactive Data File (embedded with the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-KEY INTERNATIONAL, INC. Date: August 14, 2024 By: /s/ Cecilia C. Welch Cecilia C. Welch Chief Financial Officer EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated August 14, 2024 issued by the Company.